BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 27, 2004
View Archived Issues
Tarceva Trial Proves Positive, Pushes OSI, Genentech Stocks
Investors adored results from a Phase III trial of an experimental cancer drug, significantly driving up stock prices of two of the companies involved in its development. (BioWorld Today)
Read More
CV Therapeutics Begins Second Phase III Trial Of Regadenoson
Read More
Antisoma's Stock Falls On Phase III Miss With R1549
Read More
BioWorld Biotechnology State of the Industry Report 2004 now available
Read More
Advancing Three Cancer Drugs, Salmedix Takes Aim At $86M IPO
Read More
Other News To Note
Read More